Antiplatelet Drugs: Bleeding and Decompensation Events
For one study, researchers sought to determine whether or not these drugs were linked to cirrhosis-related problems such as bleeding and portal hypertension. Using the IMS PharMetrics database, they were able to identify privately insured adults diagnosed with cirrhosis between the years 2007 and 2015. These patients were then categorized as compensated or decompensated based on whether or not they had hypertensive complications. portales 1 year before their cirrhosis. diagnostic. Using a historical analysis design, findings of bleeding or decompensation were assessed between 6 and 18 months after diagnosis of cirrhosis. Associations between exposure to anticoagulants (AC), antiplatelets (AP), and nonsteroidal anti-inflammatory drugs (NSAIDs) were analyzed using a multivariable Cox proportional hazards regression model, and the results were adjusted for variable effects. The survey included a total of 18,070 patients with cirrhosis, of which 57% were men, 74% aged between 50 and 64 and 34% who had already suffered decompensation. In total, there were 1,231 (7%) claims for NSAIDs, 377 (2%) for anticoagulants and 385 (2%) for antiplatelets. In a landmark 9-month study, PAs were found to be linked to greater bleeding [adjusted hazard ratio (aHR)=1.31; 95% CI: 1.00, 1.72] and decompensation episodes (aHR = 1.44; 95% CI: 1.06, 1.95]. In a 3-month historical analysis, the association between NSAIDs and bleeding episodes was statistically significant (aHR = 1.29; 95% CI: 1.06, 1.57) Adjusted analyses, no association was found between AC and bleeding or decompensation outcomes No statistically significant association was found PA use was linked to an increase in the number of patients who experienced bleeding and decompensation episodes These results were found in patients who were privately insured NSAID use was linked to bleeding significant early but not with decompensations In conclusion, CAs were not associated with bleeding or decompensation outcomes.
Source – journals.lww.com/jcge/Abstract/2022/08000/Antiplatelet_Medications_Are_Associated_With.12.aspx